|
π¦
|
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
10 auth.
H. Yu,
M. Arcila,
N. Rekhtman,
C. Sima,
M. Zakowski,
W. Pao,
...
M. Kris,
V. Miller,
M. Ladanyi,
Gregory Riely
|
11 |
2013 |
11
π¦
|
|
π
|
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
11 auth.
P. Paik,
A. Drilon,
P. Fan,
H. Yu,
N. Rekhtman,
M. Ginsberg,
...
L. Borsu,
N. Schultz,
M. Berger,
C. Rudin,
M. Ladanyi
|
9 |
2015 |
9
π
|
|
π
|
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
36 auth.
E. Jordan,
H. R. Kim,
M. Arcila,
D. Barron,
D. Chakravarty,
Jianjiong Gao,
Matthew T. Chang,
A. Ni,
Ritika Kundra,
P. Jonsson,
G. Jayakumaran,
S. Gao,
Hannah C. Johnsen,
Aphrothiti J. Hanrahan,
A. Zehir,
...
N. Rekhtman,
M. Ginsberg,
Bob T. Li,
H. Yu,
P. Paik,
A. Drilon,
M. Hellmann,
Dalicia Reales,
R. Benayed,
V. Rusch,
M. Kris,
J. Chaft,
J. Baselga,
B. Taylor,
N. Schultz,
C. Rudin,
D. Hyman,
M. Berger,
D. Solit,
M. Ladanyi,
Gregory Riely
|
8 |
2017 |
8
π
|
|
π
|
Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4).
34 auth.
C. Bosetti,
E. Lucenteforte,
E. Lucenteforte,
D. Silverman,
G. Petersen,
P. Bracci,
B. Ji,
E. Negri,
Donghui Li,
H. Risch,
S. Olson,
S. Gallinger,
A. Miller,
H. Bueno-de-Mesquita,
R. Talamini,
...
J. Polesel,
P. Ghadirian,
P. Baghurst,
W. ZatoΕski,
E. Fontham,
W. Bamlet,
E. Holly,
P. Bertuccio,
Yu-tang Gao,
M. A. Hassan,
H. Yu,
R. Kurtz,
M. Cotterchio,
M. Cotterchio,
J. Su,
P. Maisonneuve,
E. Duell,
P. Boffetta,
C. Vecchia
|
8 |
2012 |
8
π
|
|
π
|
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
7 auth.
Γ. Quintanal-Villalonga,
J. Chan,
H. Yu,
D. Peβer,
C. Sawyers,
T. Sen,
...
C. Rudin
|
8 |
2020 |
8
π
|
|
π
|
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
25 auth.
T. Sundaresan,
L. Sequist,
J. Heymach,
Gregory Riely,
P. JΓ€nne,
W. Koch,
J. Sullivan,
Douglas B. Fox,
R. Maher,
A. Muzikansky,
A. Webb,
H. Tran,
U. Giri,
M. Fleisher,
H. Yu,
...
Wen Wei,
B. Johnson,
T. Barber,
John R. Walsh,
J. Engelman,
Shannon L. Stott,
R. Kapur,
S. Maheswaran,
M. Toner,
D. Haber
|
8 |
2015 |
8
π
|
|
π
|
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
21 auth.
N. Marcoux,
S. Gettinger,
G. OβKane,
K. Arbour,
J. Neal,
H. Husain,
T. Evans,
J. Brahmer,
A. Muzikansky,
P. Bonomi,
...
S. D. Del Prete,
A. Wurtz,
A. Farago,
D. Dias-Santagata,
M. MinoβKenudson,
K. Reckamp,
H. Yu,
H. Wakelee,
F. Shepherd,
Z. Piotrowska,
L. Sequist
|
8 |
2019 |
8
π
|
|
π
|
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant NonβSmall Cell Lung Cancer
16 auth.
K. Arbour,
E. Jordan,
H. R. Kim,
Jordan A. Dienstag,
H. Yu,
F. SΓ‘nchez-Vega,
P. Lito,
M. Berger,
D. Solit,
M. Hellmann,
...
M. Kris,
C. Rudin,
A. Ni,
M. Arcila,
M. Ladanyi,
Gregory Riely
|
8 |
2017 |
8
π
|
|
π¦
|
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
13 auth.
H. Yu,
C. Sima,
James Huang,
S. Solomon,
A. Rimner,
P. Paik,
M. Pietanza,
C. Azzoli,
N. Rizvi,
L. Krug,
...
V. Miller,
M. Kris,
Gregory Riely
|
8 |
2013 |
8
π¦
|
|
π
|
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
15 auth.
G. Oxnard,
J.C. Yang,
H. Yu,
Sang We Kim,
H. Saka,
L. Horn,
K. Goto,
Y. Ohe,
H. Mann,
K. Thress,
...
M. Frigault,
K. Vishwanathan,
D. Ghiorghiu,
S. Ramalingam,
M. Ahn
|
8 |
2020 |
8
π
|
|
π
|
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
18 auth.
L. Sequist,
Ji-Youn Han,
M. Ahn,
B. Cho,
H. Yu,
Sang-We Kim,
J. Yang,
J. Lee,
W. Su,
D. Kowalski,
...
S. Orlov,
M. Cantarini,
R. Verheijen,
A. Mellemgaard,
L. Ottesen,
P. Frewer,
X. Ou,
G. Oxnard
|
8 |
2020 |
8
π
|
|
π’
|
Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes.
17 auth.
M. Offin,
J. Chan,
M. Tenet,
H. Rizvi,
R. Shen,
Gregory Riely,
N. Rekhtman,
Y. Daneshbod,
Γ. Quintanal-Villalonga,
A. Penson,
...
M. Hellmann,
M. Arcila,
M. Ladanyi,
D. Peβer,
M. Kris,
C. Rudin,
H. Yu
|
8 |
2019 |
8
π’
|
